In most oncological diseases, overexpression of the anti-apoptotic protein BCL-2 inhibits the BAX protein and its activators, leading to tumour growth and its resistance to the applied therapy16–20. Homolog cell production from viruses, similarly to Bcl-2 proteins, inhibits apoptosis and death of infected cells 21. Cells missing both Bak and BAX proteins are resistant to cytochrome C promotion and apoptosis 22. At the moment, studies concerning BAX activation substances in acute leukaemia are still in progress 23. Disturbances in apoptosis, guided by increased accumulation of BCL-2, are responsible not only for oncological but also for autoimmunological diseases 22,24,25. Mason et al. indicated that the absence of BAK/BAX expression in mice promotes a deadly disease similar to lupus 24. Less severe symptoms were noted in mice with an isolated lack of BAK, though never in those with an isolated lack of BAX. Regulation of apoptosis in inflammatory diseases by intracellular peptides and signalling proteins is not fully understood yet 26. Fan et al. examined the eosinophilic apoptosis in the mucous membrane of patients with chronic allergic rhinosinusitis with increased BAX expression. The authors observed no differences in the superficial and deep layers of the mucous membrane 27. The role of BCL-2 and BAX in sinus mucosal inflammation was also studied using Staphylococcus aureus, confirming their importance in the bacteria-induced apoptosis of olfactory cells 28. Tesfaigzi et al. observed that respiratory tract exposure to environmental allergens or toxins might cause mucous membrane damage, followed by inflammatory response and lower expression of BCL-2 protein 2. Recovery means reducing the number of cells to the state before damage/inflammation, with temporarily decreased expression of Bcl-2 as an apoptosis inhibitor 29. Cohen et al. examined decreased levels of Bcl-2 in patients with bronchial asthma and apoptosis inhibition 10. We also reported increased levels of BAX mRNA and decreased levels of Bcl-2 in mucous membrane of patients with CRSwNP, which confirms sinus mucosa damage, followed by inflammatory process and apoptosis inhibition.
The BAX/BCL-2 ratio is considered a prognostic biomarker for cancer aggressiveness5,30−32. The authors examining melanoma progression found reduced apoptosis, overexpression of BCL-2, low expression of the BAX protein, and a lack of mutation in coding sequence proteins 32. The increased BAX/BCL-2 ratio has also been used as an independent predictive marker in experimental studies evaluating damaged nervous tissues in patients with miastenia gravis 33,34. In our examined patients with CRSwNP, the BAX/BCL-2 ratio increased, which may be associated with increased apoptosis.
The tumor suppressor oncoprotein-p53, known as “the guardian of the genome,” regulates gene transcription responsible for, e.g., DNA repair, cell cycle, ageing and proliferation processes35–37. Cell cycle repression and apoptosis play a similar role in oncogenesis suppression. Due to proteins antagonistic bifunctionality, a single cell action enables an accurate reaction for changing environmental conditions 38. Mutation in the p53 genome is characteristic of most cancers 39. However, Ingle et al. suggested that in benign epithelial lesions of the upper respiratory tract, the accumulation of p53 protein can occur without gene mutation37. We found higher levels of P53 transcripts in patients with CRSwNP, which corresponded with increased proliferation of epithelial cells.
The p21 is a multifunctional protein regulating the cell cycle and ensuring genome stability in response to various stimuli, including DNA damage 40. The transcription of p21 is regulated by p53-dependent and -independent pathways 41. The mutation of the p21 genome is rarely detected 42. In oncological patients, an analysis of P53 and P21 expression in predicting the effects of treatment was important 43. An increased vulnerability to apoptosis with p53 in cells lacking p21 was observed in colorectal cancer 44.
A higher expression of p53 in CRSwNP was reported in 1999 by Lavezzi et al.45. Garavello et al. noted overexpression of p53 and Bcl-2 and increased apoptosis in mucous membranes with polyps, compared to the healthy sinus mucous membranes with an unchanged expression of the p21 protein 46. Chalastras et al. examined patients with chronic rhinosinusitis and reported an increased tendency toward proliferation and decreased apoptosis in epithelial cells, increased expression of p53 and decreased levels of Bcl-2 in hyperplastic polyps36. On the other hand, Küpper et al. reported decreased expression of p53 in patients with CRSwNP 9. Therefore, the expression of p53 in CRSwNP varies greatly. The reason may be, in some experiments authors using as study control, fragments of tissue collected from different anatomical locations (e.g., sinuses, nasal cavity, inferior nasal turbine) or perhaps because different diagnostic methods were used 9,36,45. When p53 protein accumulation is reported with immunohistochemical studies, it does not always respond with its genome mutation. The accumulation of p53 antigen in healthy cells may be very discreet and difficult to estimate 36,37. We observed a higher expression of the p53 and p21 proteins in patients with CRSwNP, but the p53/p21 ratio was similar in both study groups.
Elevated levels of BAX, P53, P21 genes and reduced levels of Bcl-2 evidenced increased mucosal apoptosis in patients with CRSwNP. Disorders of apoptosis may include the oncogenic c-MYC, which codes for transcription factors, regulates processes required for cell growth and oncogenesis, and affects Bcl-2 expression levels. According to Jung, c-MYC activation is correlated with increased expression of CCND1 and lower expression of Bcl-2 and p2147. Our study reported higher expression mRNA levels of c-MYC and p21 and lower expression levels of Bcl-2 and CCND1. According to literature data, these findings are, however partially contradictory.
We also detected a significantly higher expression of Apaf-1, CASP3 and CASP9, contributing to the induction of apoptotic processes in CRSwNP. APAF-1 is a cytosolic protein that activates caspase-9, a key factor in the apoptotic pathway of mitochondrial cells 48. In healthy cells, APAF-1 remains in its autoinhibited form, and CASP-3 and CASP-9 remain inactive49. Cho et al. reported no apparent difference in CASP3 expression levels between normal mucosa and mucosa with nasal polyps50. CRSwNP can be, however, compared to other inflammatory processes. Hou and Xing found increased expression levels of p53, CASP3 and CASP9 and decreased expression levels of Bcl-2 in patients with RA 51. Our results suggest a similar inflammation pattern.
BIRC5 is a gene (survivin), which acts as a prognostic biomarker in neoplastic diseases, indirectly inhibits apoptosis and promotes cell proliferation. Qui et al. found that its overexpression, associated with immune response 52,53, may play a key role in nasal polyps development 54. However, these authors examined mucosal samples from various locations (turbinate, tissue surrounding polyps and nasal polyps) 54. Cho et al., who examined mucosa from the inferior turbinate, did not report higher survivin expression in healthy control and in patients with nasal polyps 50. We reported lower expression levels of BIRC5, which is characteristic of increased apoptosis. Due to its immunomodulatory effect, BIRC5 may be a potential therapeutic target whose activity can be modified by an external stimulus. However, this hypothesis requires further research.
The advantage of our study relies on tissue sampling, which allows us to compare the levels between healthy patients and CRSwNP patients. In our study, tissue samples were taken from the exact location, i.e. the maxillary sinus mucosa. The study may be limited by the small sample size, also from healthy participants. This group is however rarely accessible to examination. Increased levels of the BAX transcripts and decreased levels of BCL-2 indicated increased apoptosis in the inflamed mucous membrane of patients with CRSwNP. A comparison of p53 and p21 in the healthy control and the study group suggested disturbances in apoptosis regulation.
The small molecules, RNAs or microRNAs (miRNAs), play a crucial role in many pathways that regulate apoptosis, as in cellular proliferation, differentiation and ageing Yang. Moreover, these molecules regulate gene expression in human diseases, serving as valuable indicators of cancer progression 55,56 and in diagnosing other diseases with excessive apoptosis. Senescence strongly inhibits cell proliferation and induces IL-6 and IL-8 secretion. Bhaumik et al. showed that increased expression of miR-146a/b inhibits an excessive secretion of inflammatory cytokines 57. Sun et al. analysed miR-125-5p and miR-143/145 expressions as potential biomarkers for ischemic stroke 58. Tang et al. examined the expression level of miR-145-5p and found that it was decreased in synovial tissues of RA patients 59. Moreover, miRNA molecules are used in therapy for many diseases. Zhao et al. treated patients with traumatic brain injury with miR-203 inhibitors and reduced neuronal apoptosis by inhibiting CASP3 activity and increasing Bcl-2 expression 60.
Cimmino et al. demonstrated that miR-15a and miR-16-1 negatively regulate Bcl-2 at the post-transcriptional level 61. Moreover, it has been found that miRNAs (miR-106b or miR-29 cluster) can regulate the activity of p53 and p21 proteins in the processes of DNA damage 62,63. Liu et al. reported an association between miR-125b, miR-133, miR-146a, and miR-203 with acute exacerbation risk, inflammation, and severity of the chronic obstructive pulmonary disease. The authors reported a positive correlation with the level of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-17 and IL-23) 64. Taganov et al. suggested that miRNAs could regulate cellular immune response to particular pathogens. They found that miRNAs acted as potentially negative regulators of inflammation and showed increased expression levels of miR-132, miR-146 and miR-155 in monocytic cells as a response to bacterial infection 65. Faraoni et al. described the role of miR-155 in the immune response to inflammation, e.g., in viral infections caused by DNA viruses. Furthermore, miR-155 is involved in hematopoietic cell differentiation, cancer, and cardiovascular disease 55. The introduction of miRNA inhibitors into cells regulates response to inflammation by protecting cells against cytokine-induced death55,66.
The similar levels of miRNA-146a in patients with CSR and healthy control may explain the results from Bhaumik et al. 57, who suggested that delayed miR-146a/b induction might be a compensatory response to restrain inflammation 57. So far, no studies have investigated the role of miRNAs in CRSwNP. miRNA-203a overexpression and lower expression levels of miR-17-5p and miR-145-5p can promote increased apoptosis. The selected miR-17 was considered as a biomarker of chronic immune, cardiovascular and neurodegenerative diseases, and its overexpression is associated with autoimmunity 67. Selected miR-145-5p and miR-146a 5p exhibit anti-apoptotic roles68–70 and MiR-203a-3β overexpression is associated with increased apoptosis 71. miRNAs expression levels are variable and based on cell-specific gene expression 68. However, there is clear compliance of the direction of changes with those described in the literature.
miR-203a-3p gene, which exhibits the most potent pro-apoptotic effect, inhibits the proliferation, migration and invasion of cancer cells 72. Lee et al. suggested a link between miR-203-3p expression and human lifespan 73. Han et al. showed that higher levels of miR-203-3p expression inhibit pathological retinal angiogenesis 74. However, this does not satisfactorily explain increased apoptosis and polypoid hyperplasia in patients with CRSwNP. In the course of this disease, both processes may not be sufficiently inhibited. We suppose that miR-203a-3p, due to its pro-apoptotic effect, may play a key role in developing new treatment strategies for CRSwNP, but our hypothesis requires further research.
ConclusionsTUNEL-demonstrated significantly increased apoptosis in sinus mucosa in patients with CRSwNP was evidenced by higher mRNA levels of BAX, P53, P21, CASP3, and CASP9, APAF-1 and c-MYC, and lower levels of BCL-2 and BIRC5 transcripts.
The increased level of miR 203a-3p and decreased levels of miR 17-5p and miR-145-5p are also characteristic features of apoptosis in CRSwNP.
Due to its pro-apoptotic activity, miR 203a-3p may play an essential role in developing new treatment strategies for CRSwNP, but this hypothesis requires further studies.
In opposite, comparable levels of miR-146a in healthy patients and controls exclude its possible utility as a biomarker of CRSwNP.